drugset
Drugs / FORIGERIMOD
last change Jun 2023 re-read 3 minutes ago

FORIGERIMOD

also known as CEP-33457 · IPP-201101 · FORIGERIMOD ACETATE · Lupuzor · P-140 · Rigerimod

Protein / enzyme biologic targets HSPA8 via inhibition

Developed for
systemic lupus erythematosus
Investigated by
Cephalon · ImmuPharma

Trials 3

today NCT03427151 · Ph 3 NCT01240694 · Ph 3 NCT01135459 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 missed
Phase 2 NCT01135459 Jun 2010 → Jan 2012 systemic lupus erythematosus Cephalon Completed Missed primary
Phase 32 trials
Phase 3 NCT03427151 Feb 2018 → Feb 2019 systemic lupus erythematosus ImmuPharma Completed No outcome recorded
Phase 3 NCT01240694 Dec 2010 → Jun 2012 systemic lupus erythematosus Cephalon Terminated No outcome recorded Stop: Business
Comparator or background therapy1 trial
Phase 3 NCT02504645 Comparator Mar 2015 → Jan 2018 systemic lupus erythematosus ImmuPharma Completed No outcome recorded

Press releases naming this drug 52 releases

DateIssuerRelease
2023-06-19 ImmuPharma Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting immupharma.co.uk ↗
2023-04-19 ImmuPharma FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus immupharma.co.uk ↗
2023-03-27 ImmuPharma Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA immupharma.co.uk ↗
2022-11-18 ImmuPharma Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities immupharma.co.uk ↗
2022-09-30 ImmuPharma Lupuzor™ Update immupharma.co.uk ↗
2022-06-27 ImmuPharma Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients immupharma.co.uk ↗
2022-05-04 ImmuPharma UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION immupharma.co.uk ↗
2022-04-13 ImmuPharma UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. immupharma.co.uk ↗
2022-02-07 ImmuPharma LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently immupharma.co.uk ↗
2021-02-09 ImmuPharma Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021 immupharma.co.uk ↗
2020-11-20 ImmuPharma FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients immupharma.co.uk ↗
2020-11-10 ImmuPharma Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients immupharma.co.uk ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as FORIGERIMOD ChEMBL registry synonym — accepted as the source's own label CHEMBL3989409 ↗
Known as CEP-33457 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01240694 ↗
1

NCT01135459 ↗
Known as FORIGERIMOD ACETATE ChEMBL registry synonym — accepted as the source's own label CHEMBL3989409 ↗
Known as IPP-201101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03427151 ↗
1

NCT02504645 ↗
Known as Lupuzor ChEMBL registry synonym — accepted as the source's own label CHEMBL3989409 ↗
Known as P-140 ChEMBL registry synonym — accepted as the source's own label CHEMBL3989409 ↗
Known as Rigerimod ChEMBL registry synonym — accepted as the source's own label CHEMBL3989409 ↗
Action Inhibit “Heat shock cognate 71 kDa protein inhibitor” CHEMBL3989409 ↗
Modality Protein / enzyme biologic — CHEMBL3989409 ↗
Route Subcutaneous “Participants were randomized to receive either CEP-33457 or placebo subcutaneously (SC) every 4 weeks.” NCT01135459 ↗
Target HSPA8 “Heat shock cognate 71 kDa protein inhibitor” CHEMBL3989409 ↗